Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Assets (2016 - 2025)

Historic Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $280.7 million.

  • Enanta Pharmaceuticals' Assets fell 2546.65% to $280.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.7 million, marking a year-over-year decrease of 2546.65%. This contributed to the annual value of $280.7 million for FY2025, which is 2546.65% down from last year.
  • Enanta Pharmaceuticals' Assets amounted to $280.7 million in Q3 2025, which was down 2546.65% from $301.0 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Assets high stood at $495.2 million for Q2 2023, and its period low was $280.7 million during Q3 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Assets averaged around $393.0 million, with its median value being $398.8 million (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Assets skyrocketed by 2854.39% in 2023, and later plummeted by 2546.65% in 2025.
  • Enanta Pharmaceuticals' Assets (Quarter) stood at $440.6 million in 2021, then dropped by 21.12% to $347.5 million in 2022, then grew by 23.3% to $428.5 million in 2023, then fell by 18.64% to $348.6 million in 2024, then fell by 19.48% to $280.7 million in 2025.
  • Its Assets was $280.7 million in Q3 2025, compared to $301.0 million in Q2 2025 and $323.0 million in Q1 2025.